The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to ...

With both a label expansion and a conversion to a full approval, Eli Lilly has earned the FDA’s go-ahead to act on the ...

Pirtobrutinib is now FDA-approved for relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, following its 2023 accelerated approval. The BRUIN-CLL-321 trial showed pirtobrutinib ...

Thrombotic risk with PICCs matched that of totally implantable venous access devices, showing comparable long-term safety.

CD19-targeted therapy Breyanzi (lisocabtagene maraleucel) can now be used to treat adults with MZL – a rare and form of ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...

Other abstracts will offer data on bispecifics moving into frontline therapy; examples include data coming Saturday from EPCORE-NHL2 involving epcoritamab in diffuse large B-cell lymphoma, and the ...

The decision broadens Jaypirca’s label and converts the December 2023 accelerated approval to a traditional approval status.

The FDA has granted traditional approval to pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or ...